Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1993 1
1997 24
1998 108
1999 117
2000 161
2001 198
2002 186
2003 235
2004 275
2005 317
2006 364
2007 410
2008 491
2009 570
2010 664
2011 754
2012 851
2013 1034
2014 1111
2015 1204
2016 1104
2017 1235
2018 1253
2019 1265
2020 1313
2021 1280
2022 1140
2023 971
2024 978
2025 1207
2026 148

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18,633 results

Results by year

Filters applied: . Clear all
Page 1
Mechanisms of PTEN loss in cancer: It's all about diversity.
Álvarez-Garcia V, Tawil Y, Wise HM, Leslie NR. Álvarez-Garcia V, et al. Semin Cancer Biol. 2019 Dec;59:66-79. doi: 10.1016/j.semcancer.2019.02.001. Epub 2019 Feb 7. Semin Cancer Biol. 2019. PMID: 30738865 Review.
Accordingly, with the exceptions of glioblastoma and endometrial cancer, mutations of the PTEN coding sequence are uncommon (<10%) in most types of cancer. Here we review the data relating to PTEN loss in seven common tumour types and discuss mechan …
Accordingly, with the exceptions of glioblastoma and endometrial cancer, mutations of the PTEN coding sequence are uncommon (& …
The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. Carnero A, et al. Curr Cancer Drug Targets. 2008 May;8(3):187-98. doi: 10.2174/156800908784293659. Curr Cancer Drug Targets. 2008. PMID: 18473732 Review.
Many components of this pathway have been described as causal forces in cancer. PTEN activity is lost by mutations, deletions or promoter methylation silencing at high frequency in many primary and metastatic human cancers. Germ line mutations of PTEN …
Many components of this pathway have been described as causal forces in cancer. PTEN activity is lost by mutations, deletions …
PTEN.
Worby CA, Dixon JE. Worby CA, et al. Annu Rev Biochem. 2014;83:641-69. doi: 10.1146/annurev-biochem-082411-113907. Annu Rev Biochem. 2014. PMID: 24905788 Review.
The importance of PTEN in cellular function is underscored by the frequency of its deregulation in cancer. ...Although the role of PTEN in cancers has long been appreciated, it is also emerging as an important factor in other diseases, such as diabetes …
The importance of PTEN in cellular function is underscored by the frequency of its deregulation in cancer. ...Although the rol …
Interruption of KLF5 acetylation promotes PTEN-deficient prostate cancer progression by reprogramming cancer-associated fibroblasts.
Zhang B, Liu M, Mai F, Li X, Wang W, Huang Q, Du X, Ding W, Li Y, Barwick BG, Ni JJ, Osunkoya AO, Chen Y, Zhou W, Xia S, Dong JT. Zhang B, et al. J Clin Invest. 2024 May 23;134(14):e175949. doi: 10.1172/JCI175949. J Clin Invest. 2024. PMID: 38781024 Free PMC article.
Inactivation of phosphatase and tensin homolog (PTEN) is prevalent in human prostate cancer and causes high-grade adenocarcinoma with a long latency. Cancer-associated fibroblasts (CAFs) play a pivotal role in tumor progression, but it remains elusive whether …
Inactivation of phosphatase and tensin homolog (PTEN) is prevalent in human prostate cancer and causes high-grade adenocarcino …
Transcriptional landscape of PTEN loss in primary prostate cancer.
Imada EL, Sanchez DF, Dinalankara W, Vidotto T, Ebot EM, Tyekucheva S, Franco GR, Mucci LA, Loda M, Schaeffer EM, Lotan T, Marchionni L. Imada EL, et al. BMC Cancer. 2021 Jul 26;21(1):856. doi: 10.1186/s12885-021-08593-y. BMC Cancer. 2021. PMID: 34311724 Free PMC article.
BACKGROUND: PTEN is the most frequently lost tumor suppressor in primary prostate cancer (PCa) and its loss is associated with aggressive disease. ...We also show that contrary to what is observed in other cancers, PTEN loss in PCa leads to increased a …
BACKGROUND: PTEN is the most frequently lost tumor suppressor in primary prostate cancer (PCa) and its loss is associated with …
PTEN in cancer associated fibroblasts.
Lefler JE, Seward C, Ostrowski MC. Lefler JE, et al. Adv Cancer Res. 2022;154:203-226. doi: 10.1016/bs.acr.2022.01.002. Epub 2022 Mar 18. Adv Cancer Res. 2022. PMID: 35459470
Inactivation of PTEN in the stroma is associated with worse outcomes in human cancers, therefore, it is important to understand activities regulated downstream of PTEN in stromal compartments. Studies reviewed herein provide evidence for important mechanistic …
Inactivation of PTEN in the stroma is associated with worse outcomes in human cancers, therefore, it is important to understan …
NOTCH and PTEN in prostate cancer.
Bertrand FE, McCubrey JA, Angus CW, Nutter JM, Sigounas G. Bertrand FE, et al. Adv Biol Regul. 2014 Sep;56:51-65. doi: 10.1016/j.jbior.2014.05.002. Epub 2014 May 22. Adv Biol Regul. 2014. PMID: 24933481 Review.
Over the past decade, our understanding of the role that Notch-signaling has in tumorigenesis has shifted from leukemogenesis into cancers of solid tumors. Emerging data suggests that in addition to direct effects mediated through the canonical Notch pathway, Notch may par …
Over the past decade, our understanding of the role that Notch-signaling has in tumorigenesis has shifted from leukemogenesis into cancer …
Breast cancer risk and clinical implications for germline PTEN mutation carriers.
Ngeow J, Sesock K, Eng C. Ngeow J, et al. Breast Cancer Res Treat. 2017 Aug;165(1):1-8. doi: 10.1007/s10549-015-3665-z. Epub 2015 Dec 23. Breast Cancer Res Treat. 2017. PMID: 26700035 Review.
Breast cancer risk estimates (67-85 %) for women with germline PTEN mutations are similar to those quoted for patients with germline mutations in the BRCA1/2 genes. ...However, many of the benign features of CS are common in the general population, making the diagno …
Breast cancer risk estimates (67-85 %) for women with germline PTEN mutations are similar to those quoted for patients with ge …
PTEN at the crossroad of metabolic diseases and cancer in the liver.
Vinciguerra M, Foti M. Vinciguerra M, et al. Ann Hepatol. 2008 Jul-Sep;7(3):192-9. Ann Hepatol. 2008. PMID: 18772845 Free article. Review.
The tumor suppressor PTEN is a phosphoinositide phosphatase regulating the PI3K/Akt signaling pathways and mutated or deleted in a variety of human cancers. ...Finally, PTEN mutations/deletions or low PTEN expression are associated with diverse liver m …
The tumor suppressor PTEN is a phosphoinositide phosphatase regulating the PI3K/Akt signaling pathways and mutated or deleted in a va …
Discovery of CHD1 Antagonists for PTEN-Deficient Prostate Cancer.
Johnson RL, Graboski AL, Li F, Norris-Drouin JL, Walton WG, Arrowsmith CH, Redinbo MR, Frye SV, James LI. Johnson RL, et al. J Med Chem. 2024 Nov 28;67(22):20056-20075. doi: 10.1021/acs.jmedchem.4c01172. Epub 2024 Nov 7. J Med Chem. 2024. PMID: 39508435 Free PMC article.
A cocrystal structure revealed a unique binding mode and competition pull-down experiments in cell lysates confirmed endogenous target engagement. Treatment of PTEN-deficient prostate cancer cells with UNC10142 led to a dose-dependent reduction in viability while …
A cocrystal structure revealed a unique binding mode and competition pull-down experiments in cell lysates confirmed endogenous target engag …
18,633 results
You have reached the last available page of results. Please see the User Guide for more information.